Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) announced its quarterly earnings results on Thursday. Halozyme Therapeutics Stock Up 20.2%NASDAQ HALO traded up $17.36 during trading hours on Friday, hitting $103.12. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $103.30. Halozyme Therapeutics Company Profile(Get Free Report)Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. See AlsoReceive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.